নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

actavis group ptc ehf - valsartan / hydroklortiazid - tablett, filmdrasjert - 320 mg / 25 mg

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

hexal a/s - ramipril - tablett - 10 mg

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

hexal a/s - ramipril - tablett - 1.25 mg

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

hexal a/s - ramipril - tablett - 2.5 mg

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

hexal a/s - ramipril - tablett - 5 mg

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

astrazeneca - lisinoprildihydrat - tablett - 10 mg

ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

les laboratoires servier - trifluridine, tipiracil hydrochloride - colorektale neoplasmer - antineoplastiske midler - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastiske midler - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

pharmathen s.a. - irbesartan - hypertensjon - agenter som virker på renin-angiotensinsystemet - sabervel er indisert hos voksne til behandling av essensiell hypertensjon. det er også angitt for behandling av nyresykdom hos voksne pasienter med hypertensjon og type 2 diabetes mellitus som en del av en antihypertensive legemidler produktet diett.

ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - tiotepa - hematopoietic stem cell transplantation; neoplasms - antineoplastiske midler - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.